$1.51B in CY2024 Part D spend176K claims · 46K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Venetoclax used for?
VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, o....
Is there a generic for Venetoclax?
No. Venetoclax is brand-only with no generic equivalents currently in market.
How much does my plan pay for Venetoclax?
NADAC pricing data not currently available for this drug.
Is Venetoclax on the FDA shortage list?
No. Venetoclax is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.